Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Manuel Romero‐Gómez, Eric Lawitz, R. Ravi Shankar, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 4, pp. 888-897
Open Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 332
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 112
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 97
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Stephen A. Harrison, Juan P. Frías, Guy Neff, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 12, pp. 1080-1093
Closed Access | Times Cited: 95
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Arun J. Sanyal, Lee M. Kaplan, Juan P. Frías, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2037-2048
Open Access | Times Cited: 63
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 62
NAFLD and NASH: etiology, targets and emerging therapies
Shulin Wei, Li Wang, Paul C. Evans, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103910-103910
Closed Access | Times Cited: 57
Hepatic glucose metabolism in the steatotic liver
Egeria Scoditti, Silvia Sabatini, Fabrizia Carli, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 5, pp. 319-334
Closed Access | Times Cited: 36
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Stephen A. Harrison, Sarah K. Browne, John J. Suschak, et al.
Journal of Hepatology (2024)
Open Access | Times Cited: 32
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 31
Obesity and the kidney: mechanistic links and therapeutic advances
Kevin Yau, Rachel Kuah, David Z.I. Cherney, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 6, pp. 321-335
Closed Access | Times Cited: 31
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Tong Bu, Ziyan Sun, Yi Pan, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 3, pp. 354-372
Open Access | Times Cited: 23
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
Xiaolong Qi, Jie Li, Cyrielle Caussy, et al.
Hepatology (2024)
Open Access | Times Cited: 19
MASH clinical trials and drugs pipeline: An impending tsunami
Mazen Noureddin
Hepatology (2024)
Closed Access | Times Cited: 17
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Jian‐Gao Fan, Xiaoyuan Xu, Rui-Xu Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 16
Glucagon‐Like Peptide‐1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes
Chia‐Chih Kuo, Min‐Hsiang Chuang, Chun‐Hsien Li, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 4
GPCR drug discovery: new agents, targets and indications
José A. Lorente, Aleksandr V. Sokolov, Gavin Ferguson, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 4
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions
Naveed Sattar, Matthew M.Y. Lee
The Lancet Diabetes & Endocrinology (2025)
Closed Access | Times Cited: 3
Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical Options
Emmanouil Koullias, Maria Papavdi, John Koskinas, et al.
Cureus (2025)
Open Access | Times Cited: 2
Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs
Xing Wan, Jingyuan Ma, He Bai, et al.
Biomolecules (2025) Vol. 15, Iss. 1, pp. 140-140
Open Access | Times Cited: 2
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Sten Madsbad, Jens J. Holst
Expert Opinion on Investigational Drugs (2025), pp. 1-19
Open Access | Times Cited: 2
Consensus Guidelines for the Diagnosis and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Adult Asian Indians with Type 2 Diabetes
Anoop Misra, Ashish Kumar, Mohammad Shafi Kuchay, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2025) Vol. 19, Iss. 3, pp. 103209-103209
Closed Access | Times Cited: 2
Metabolic dysfunction-associated steatotic liver disease and the heart
Stan Driessen, Sven Francque, Stefan D. Anker, et al.
Hepatology (2023)
Open Access | Times Cited: 31
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Robert M. Gutgesell, Rubén Nogueiras, Matthias H. Tschöp, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1069-1084
Open Access | Times Cited: 14
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
Eric Lawitz, Mandy Fraessdorf, Guy Neff, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 5, pp. 837-846
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top